鉴于高危 HPV 基因型（例如 HPV 16 和 18）与宫颈癌之间存在密切关联，本研究旨在将伊朗西南部人群中常见 HPV 基因型的分布与现有疫苗中包含的基因型进行比较。使用三种不同的方法（自动化仪器、柱和沉淀）从研究中的 8036 名个体的生物样本中提取 DNA，并使用实时 PCR 检测出总共 21 种不同的 HPV 基因型。女性（>99%），HPV感染阳性率为29.9%，其中高危基因型占84.9%。 HPV感染率最高年龄≤30岁（35.9%）。 HPV 6 和 16 分别是最常见的低风险和高风险基因型。 35%的阳性样本中观察到多种HPV感染，其中HPV6和16之间的交叉感染最高。在21个阳性样本（1%）中观察到HPV 16和18的共同感染。尽管疫苗接种对于减少 HPV 感染（例如宫颈癌）的结果至关重要，但其他经常出现的高危基因型并不包含在 9 价疫苗中。由于宫颈癌与其他高危 HPV 类型之间的关联性而非 16其中18种研究较少，建议调查其对宫颈癌的致病性。此外，新一代 HPV 疫苗应包含除目前已批准疫苗涵盖的基因型之外的其他经常出现的高风险基因型。© 2024。作者获得 Springer Nature B.V. 的独家许可。

Given the strong association between high-risk HPV genotypes, such as HPV 16 and 18, and cervical cancer, this study aimed to compare the distribution of common HPV genotypes in the southwest Iranian population with those included in the available vaccines.Based on the sample quality, DNA was extracted from the biological samples of 8036 individuals included in the study using three different methods (automated instrument, column, and precipitation), and a total of 21 different HPV genotypes were detected using real-time PCR.The majority of participants were women (> 99%), with a positive rate of HPV infection of 29.9%, in which high-risk genotypes were dominant in 84.9% cases. The highest rate of HPV infections was observed in the age ≤ 30 years (35.9%). HPV 6 and 16 were the most frequent low- and high-risk genotypes, respectively. Multi HPV infections were observed in 35% of positive samples and the highest cross infections were observed between HPV6 and 16. Co-infection with HPV 16 and 18 was observed in 21 positive samples (1%). Although vaccination is essential to reduce the outcome of HPV infections, such as cervical cancer, other frequently occurring high-risk genotypes are not included in the 9-valent vaccine.Since the association between cervical cancer and other high-risk HPV types rather than 16 and 18 has been less studied, investigating their pathogenicity in cervical cancer is recommended. Furthermore, the new generation of HPV vaccines should contain other frequently occurring high-risk genotypes beyond those currently covered in approved vaccines.© 2024. The Author(s), under exclusive licence to Springer Nature B.V.